

W. J. "BILLY" TAUZIN, LOUISIANA  
RALPH M. HALL, TEXAS  
MICHAEL BILIRAKIS, FLORIDA  
FRED UPTON, MICHIGAN  
CLIFF STEARNS, FLORIDA  
PAUL E. GILLMOR, OHIO  
JAMES C. GREENWOOD, PENNSYLVANIA  
CHRISTOPHER COX, CALIFORNIA  
NATHAN DEAL, GEORGIA  
RICHARD BURR, NORTH CAROLINA  
ED WHITFIELD, KENTUCKY  
CHARLIE NORWOOD, GEORGIA  
BARBARA CUBIN, WYOMING  
JOHN SHIMKUS, ILLINOIS  
HEATHER WILSON, NEW MEXICO  
JOHN B. SHADEGG, ARIZONA  
CHARLES W. "CHIP" PICKERING, MISSISSIPPI  
VITO FOSSELLA, NEW YORK  
STEVE BUYER, INDIANA  
GEORGE RADANOVICH, CALIFORNIA  
CHARLES F. BASS, NEW HAMPSHIRE  
JOSEPH R. PITTS, PENNSYLVANIA  
MARY BONO, CALIFORNIA  
GREG WALDEN, OREGON  
LEE TERRY, NEBRASKA  
MIKE FERGUSON, NEW JERSEY  
MIKE ROGERS, MICHIGAN  
DARRELL E. ISSA, CALIFORNIA  
C.L. "BUTCH" OTTER, IDAHO  
JOHN SULLIVAN, OKLAHOMA

ONE HUNDRED EIGHTH CONGRESS

**U.S. House of Representatives**  
**Committee on Energy and Commerce**  
**Washington, DC 20515-6115**

JOE BARTON, TEXAS  
CHAIRMAN

November 18, 2004

JOHN D. DINGELL, MICHIGAN  
HENRY A. WAXMAN, CALIFORNIA  
EDWARD J. MARKEY, MASSACHUSETTS  
RICK BOUCHER, VIRGINIA  
EDOLPHUS TOWNS, NEW YORK  
FRANK PALLONE, JR., NEW JERSEY  
SHERROD BROWN, OHIO  
BART GORDON, TENNESSEE  
PETER DEUTSCH, FLORIDA  
BOBBY L. RUSH, ILLINOIS  
ANNA G. ESHOO, CALIFORNIA  
BART STUPAK, MICHIGAN  
ELIOT L. ENGE, NEW YORK  
ALBERT R. WYNN, MARYLAND  
GENE GREEN, TEXAS  
KAREN MCCARTHY, MISSOURI  
TED STRICKLAND, OHIO  
DIANA DI GETTE, COLORADO  
LOIS CAPPS, CALIFORNIA  
MICHAEL F. DOYLE, PENNSYLVANIA  
CHRISTOPHER JOHN, LOUISIANA  
TOM ALLEN, MAINE  
JIM DAVIS, FLORIDA  
JAN SCHAKOWSKY, ILLINOIS  
HILDA L. SOLIS, CALIFORNIA  
CHARLES A. GONZALEZ, TEXAS

BUD ALBRIGHT, STAFF DIRECTOR

Howard Pien  
President, Chief Executive Officer and  
Chairman of the Board  
Chiron Corporation  
4560 Horton Street  
Emeryville, CA 94608-2916

Dear Mr. Pien:

As part of its continuing oversight of matters of public health, the Committee is examining issues surrounding the recent loss of nearly half of the flu vaccine needed by the United States this year as a result of contamination at the Liverpool, UK manufacturing facility of Chiron Corporation ("Chiron"). We are deeply troubled by this sudden shortage of U.S. supplies of flu vaccine.

Of particular concern is the question of whether Chiron and/or the U.S. Government had sufficient notice from available evidence to take additional steps to safeguard against this sudden shortage. According to news reports, in late August 2004, Chiron discovered bacterial contamination in its Liverpool UK plant where it makes Fluvirin, the commercial name of the flu vaccine on order from the U.S. The U.S. Food and Drug Administration ("FDA") learned of the situation shortly after its discovery and coincidentally had a team at Chiron at the time on another matter and they were able to begin a review of the issue. This was not the first time, however, that the FDA had encountered problems at this Chiron facility. In June 2003, shortly after Chiron purchased the Liverpool plant, the FDA conducted an inspection of the site and found quality-control problems and contamination at an early stage of the production process, but these issues were reportedly resolved.

Another question of interest is whether Chiron and the U.S. Government should have taken immediate steps when the contamination came to light to ascertain better the precise scope of the problem and to react more effectively to protect the public health. On August 26, 2004, Chiron publicly disclosed its discovery of contamination of some flu vaccine lots and shortly thereafter received inspectors from the UK Medicines and

Healthcare products Regulatory Agency ("MHRA") to assess the situation. MHRA suspended Chiron's license on October 5, 2004, thereby revealing more widespread contamination of the vaccine lots. It is our understanding that the U.S. Government has claimed that it was not aware of the more widespread contamination until about the time the MHRA took action in early October 2004.

The safety and availability of the medicines needed for public health in the U.S. are of paramount concern to this Committee and, as such, we request that, pursuant to Rules X and XI of the U.S. House of Representatives, you provide us the information requested below by Wednesday, December 1, 2004:

1. All records relating to any potential, possible or actual contamination of flu vaccines, at any stage of manufacture, at your Liverpool facility.
2. All records relating to communications between Chiron and any regulator relating to any potential, possible or actual contamination of flu vaccines, at any stage of manufacture, at your Liverpool facility.
3. All records relating to public communications or statements made by Chiron, its employees or agents relating to any potential, possible or actual contamination of flu vaccines, at any stage of manufacture, at your Liverpool facility, including, but not limited to, any such public communication or statement considered, contemplated or drafted but not issued.
4. All records relating to any inspections by any regulator of your Liverpool facility that relates, in any way, to the safety and/or any potential, possible or actual contamination of flu vaccines, at any stage of manufacture, including, but not limited to:
  - a. The June 2003 inspection by the FDA;
  - b. The August 2004 inspection by the FDA;
  - c. The September 2004 inspection by the MHRA; and
  - d. The October 2004 inspection by the FDA.

Please include all records relating to any actions, contemplated, proposed or undertaken, in response to any such inspection.

5. What specific issues did the FDA identify at Chiron in the June 2003 inspection and what specific actions did Chiron take in response to each such issue?
6. Did any problems or concerns with the process, practices, techniques, standards, facilities, equipment or personnel associated with the manufacture of vaccine at Chiron's Liverpool plant identified in the

FDA's June 2003 inspection contribute, in any way, to the matters leading to the October 2004 scrapping of Chiron's vaccine production?

7. A timeline beginning with Chiron's acquisition of the Liverpool facility to the present, which includes all the following events:
  - a. Any and all events related to any potential, possible or actual contamination of vaccines, at any stage of manufacture;
  - b. All communications with any regulatory authority relating to either the safety or any potential, possible or actual contamination of vaccines, at any stage of manufacture;
  - c. All inspections by any regulator or other third party;
  - d. All public statements or communications relating to either the safety or any potential, possible or actual contamination of vaccines, at any stage of manufacture; and
  - e. All internal Chiron reports relating to either the safety or any potential, possible or actual contamination of vaccines, at any stage of manufacture.


Please produce any records relating to the information identified in this timeline, unless otherwise produced in response to this letter.

Please note that, for purposes of responding to this request, the terms "records" and "relating" should be interpreted in accordance with the attachment to this letter. If you have any questions about this matter, please contact either Anthony M. Cooke of the Majority Committee Staff at (202) 226-2424, or Chris Knauer of the Minority Committee Staff at (202) 226-3400.

Sincerely,



Joe Barton  
Chairman



John D. Dingell  
Ranking Member

Attachment

## ATTACHMENT

1. The term "records" is to be construed in the broadest sense and shall mean any written or graphic material, however produced or reproduced, of any kind or description, consisting of the original and any non-identical copy (whether different from the original because of notes made on or attached to such copy or otherwise) and drafts and both sides thereof, whether printed or recorded electronically or magnetically or stored in any type of data bank, including, but not limited to, the following: correspondence, memoranda, records, summaries of personal conversations or interviews, minutes or records of meetings or conferences, opinions or reports of consultants, projections, statistical statements, drafts, contracts, agreements, purchase orders, invoices, confirmations, telegraphs, telexes, agendas, books, notes, pamphlets, periodicals, reports, studies, evaluations, opinions, logs, diaries, desk calendars, appointment books, tape recordings, video recordings, e-mails, voice mails, computer tapes, or other computer stored matter, magnetic tapes, microfilm, microfiche, punch cards, all other records kept by electronic, photographic, or mechanical means, charts, photographs, notebooks, drawings, plans, inter-office communications, intra-office and intra-departmental communications, transcripts, checks and canceled checks, bank statements, ledgers, books, records or statements of accounts, and papers and things similar to any of the foregoing, however denominated.
2. The terms "relating," "relate," or "regarding" as to any given subject means anything that constitutes, contains, embodies, identifies, deals with, or is in any manner whatsoever pertinent to that subject, including but not limited to records concerning the preparation of other records.